Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant, Mesothelioma

Parkinson Disease 4, Autosomal Dominant Lewy Body

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Non-Small-Cell Lung

Mesothelioma, Malignant, Mesothelioma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Advanced Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Parkinson Disease 4, Autosomal Dominant Lewy Body

Locally Advanced and Metastatic Solid Tumors

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Brain Neoplasms

Uterine Cervical Neoplasms, Recurrence

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Meningeal Carcinomatosis

Inoperable Non Small Cell Lung Cancer

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Clinical Trials

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

innovaTV 301

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

MesoPDT

LEAP-006

MK-7684A-007

SKYSCRAPER-06

CheckMate 6DW

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

DREAM3R

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

CheckMate 816

CheckMate 9LA

Morpheus Lung

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

CheckMate 227

KEYVIBE-001

MK-4830-001

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

LEAP-006

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

MEK162

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

MK-3475-A17

GFPC 06-2018

PHOEBS

Intrathecal Pemetrexed for Leptomeningeal Metastasis

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

KEYNOTE-799